Skip to main content
. Author manuscript; available in PMC: 2014 Sep 22.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008042. doi: 10.1002/14651858.CD008042.pub2

Comparison 2. Zolmitriptan 10 mg versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Participants with headache relief at 30 minutes 3 449 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [1.33, 2.04]
  1.1 Oral 1 226 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.93, 1.60]
  1.2 Nasal spray 2 223 Risk Ratio (M-H, Fixed, 95% CI) 2.36 [1.67, 3.34]
2 Participants pain-free at 30 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
  2.1 Nasal spray 2 223 Risk Ratio (M-H, Fixed, 95% CI) 2.68 [1.72, 4.17]
3 Participants with headache relief at 15 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
  3.1 Nasal spray 2 223 Risk Ratio (M-H, Fixed, 95% CI) 3.90 [1.90, 8.01]
4 Participants pain-free at 15 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
  4.1 Nasal spray 2 223 Risk Ratio (M-H, Fixed, 95% CI) 3.90 [1.26, 12.05]
5 Participants using rescue medication 3 449 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.50, 0.85]
  5.1 after 30 minutes 2 350 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.46, 0.84]
  5.2 after 60 minutes 1 99 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.43, 1.33]
6 Participants with any adverse event 2 325 Risk Ratio (M-H, Fixed, 95% CI) 2.43 [1.61, 3.68]